Methylprednisolone in the management of post-COVID-19 interstitial lung disease: A randomized trial (STERCOV-ILD).
Sarcoidosis vasculitis and diffuse lung diseases · 27.03.2026 · 43 (1) · 17022-17022
DOI: 10.36141/svdld.2026.17022 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 27.03.2026. Verfasst von Aycan Yüksel und 20 weiteren Autor:innen. Beteiligte Einrichtung: TOBB Economy and Technology University Faculty of Medicine, Department of Respiratory Medicine, Ankara, Turkey. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND AND AIM: Post-COVID-19 Interstitial Lung Disease (ILD) is controversial and need for treatment is unclear.The aim of this study was to investigate the efficacy of methylprednisolone in the management of post-COVID-19 ILD in comparison to standard of care. METHODS: In this multicentre, randomized controlled clinical trial, patients with post-COVID ILD were assigned to two groups: the steroid group received oral methylprednisolone at a dose of 0.5 mg/kg/day, while the control group received supportive therapy. The primary outcome was proportion of patients with functional improvement (defined as the absence of hypoxemia/desaturation during 6MWT) at twelve-weeks. RESULTS: A total of 229 patients with post-COVID ILD patients (124 in the steroid group and 104 in the control group) completed the study. At 12-weeks, functional improvement rate was higher in the steroid group compared to the control group (74.2% vs. 55.2%, OR:2.33 [95% CI:1.34-4.06], p=0.0041). Radiological improvement was observed in 61.3% of the steroid group compared to 46.7% of the controls (OR:1.81 [95% CI:1.07-3.06], p=0.037). The mean increase in FVC (7.2% vs 3.7%, p=0.03), 6MW distance (91 vs 41 meters, p
Schlagwörter
Autor:innen und Institutionen
- TOBB Economy and Technology University Faculty of Medicine, Department of Respiratory Medicine, Ankara, Turkey.
- Recep Tayyip Erdoğan University Faculty of Medicine, Department of Respiratory Medicine, Rize, Turkey.
- Recep Tayyip Erdoğan University Faculty of Medicine, Department of Radiology, Rize, Turkey.
- Recep Tayyip Erdoğan University Faculty of Medicine, Department of Public Health, Rize, Turkey.
- Yalova Training and Research Hospital, Department of Respiratory Medicine, Yalova, Turkey.
- Kütahya Health Sciences University Faculty of Medicine, Department of Respiratory Medicine, Kütahya, Turkey.
Zitieren
APA
Yüksel, A., Karadoğan, D., Hürsoy, N., Telatar, T. G., Köse Kabil, N., Marım, F., Kaya, İ., Er, A. B., Erçelik, M., Polat Yuluğ, D., Yumrukuz Şenel, M., İlgar, C., Gültekin, Ö., Çakmakcı Karakaya, S., Yılmaz Kara, B., Özçelik, N., Selimoğlu, İ., Uyar Er, K., Kotan, A., …, & Akgün, M. (2026). Methylprednisolone in the management of post-COVID-19 interstitial lung disease: A randomized trial (STERCOV-ILD). Sarcoidosis vasculitis and diffuse lung diseases, 43(1), 17022-17022. https://doi.org/10.36141/svdld.2026.17022
Vancouver
Yüksel A, Karadoğan D, Hürsoy N, Telatar TG, Köse Kabil N, Marım F, et al. Methylprednisolone in the management of post-COVID-19 interstitial lung disease: A randomized trial (STERCOV-ILD). Sarcoidosis vasculitis and diffuse lung diseases. 2026;43(1):17022-17022. doi:10.36141/svdld.2026.17022
BibTeX
@article{Yksel2026,
author = {Yüksel, Aycan and Karadoğan, Dilek and Hürsoy, Nur and Telatar, Tahsin Gökhan and Köse Kabil, Neslihan and Marım, Feride and Kaya, İlknur and Er, Aslıhan Banu and Erçelik, Merve and Polat Yuluğ, Demet and Yumrukuz Şenel, Merve and İlgar, Ceren and Gültekin, Ökkeş and Çakmakcı Karakaya, Selin and Yılmaz Kara, Bilge and Özçelik, Neslihan and Selimoğlu, İnci and Uyar Er, Kübra and Kotan, Abdurrahman and Keskin, Hasan Veysel and Akgün, Metin},
title = {Methylprednisolone in the management of post-COVID-19 interstitial lung disease: A randomized trial (STERCOV-ILD)},
journal = {Sarcoidosis vasculitis and diffuse lung diseases},
year = {2026},
volume = {43},
number = {1},
pages = {17022--17022},
doi = {10.36141/svdld.2026.17022}
}
EUVIMED